Prescriptions and Reimbursement of Glucagon Products for Severe Hypoglycemia in Medicaid

Noah M Feder; Ryan O'Dea; Margaret Zupa; Jing Luo

doi:10.1001/jama.2024.25974

Prescriptions and Reimbursement of Glucagon Products for Severe Hypoglycemia in Medicaid

JAMA. 2025 Jan 8. doi: 10.1001/jama.2024.25974. Online ahead of print.

Authors

Noah M Feder^{1

2}, Ryan O'Dea^{3

4}, Margaret Zupa^{1

5}, Jing Luo^{1

6}

Affiliations

¹ Center for Pharmaceutical Policy and Prescribing, University of Pittsburgh, Pittsburgh, Pennsylvania.
² School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
³ Department of Epidemiology, T. H. Chan School of Public Health, Harvard University, Boston, Massachusetts.
⁴ Department of Infectious Disease, Boston Medical Center, Boston, Massachusetts.
⁵ Division of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
⁶ Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

PMID: 39775766
DOI: 10.1001/jama.2024.25974

No abstract available

Plain language summary

This study examines trends in prescribing and reimbursement for glucagon products in Medicaid before and after the introduction of these newer products.